Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 14/20 | 0.54 |
| ▸ | CX3CR1 | P49238 | 8/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841891 | 0.89 | CXCR2 (0.56) | CXCR2CX3CR1HTR1BSMN1; SMN2CXCR1 | |
| SCHEMBL842337 | 0.75 | CXCR2 (0.68) | CXCR2CX3CR1HTR1BCXCR1 | |
| SCHEMBL4693389 | 0.74 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1 | |
| SCHEMBL4693395 | 0.74 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1 | |
| SCHEMBL841935 | 0.72 | CXCR2 (0.85) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5040480 | 0.72 | CXCR2 (0.67) | CXCR2CX3CR1HTR1B | |
| SCHEMBL842566 | 0.70 | CXCR2 (0.79) | CXCR2CX3CR1HTR1B | |
| SCHEMBL842403 | 0.70 | CXCR2 (1.00) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5483535 | 0.70 | CXCR2 (0.77) | CXCR2CX3CR1HTR1B | |
| SCHEMBL5483542 | 0.70 | CXCR2 (0.77) | CXCR2CX3CR1HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | ASTRAZENECA UK LIMITED, A BRITISH CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224961-A1 | Novel thiazolo (4,5-D) pyrimidine compounds | TYMS, DPYD, TYMP | CXCR2 378/4885CX3CR1 2551/4885HTR1B 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.